David S. Barlow Joins Enzon's Board of Directors.PISCATAWAY, N.J.--(BUSINESS WIRE)--Aug. 5 , 1999-- Enzon, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ENZN) announced today the appointment of David S. Barlow, to its Board of Directors. Mr. Barlow is currently President of Pharmaceuticals at Sepracor Inc. (NASDAQ: SEPR SEPR Senior Enlisted Performance Report ). Having joined Sepracor in mid 1993, Mr. Barlow has been instrumental in Sepracor's strategic evolution into a fully integrated pharmaceutical company with a robust new product pipeline. His extensive business strategy and development experience, including several transactions with major pharmaceutical companies, is coupled with nearly fifteen years of successful strategic public policy initiatives. Mr. Barlow received his MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration from Stanford University Graduate School of Business in 1985 and his BA from Bates College in 1979. Prior to joining Sepracor in 1993, Mr. Barlow was Vice President, Worldwide Marketing and Business Development of Armour Pharmaceutical Company, a subsidiary of Rhone-Poulenc Rorer Inc. He also has held management positions in business development, planning and marketing for the Rorer Group, Pfizer, Inc. and the Ares-Serono Group. Mr. Barlow is a director of HemaSure, Inc., a publicly traded subsidiary of Sepracor. "Mr. Barlow's comprehensive experience and track record in business strategy and execution, including business development, should prove a real asset to the Enzon Board," said Peter G. Tombros, Enzon's President and Chief Executive Officer. Enzon is a biopharmaceutical company developing advanced therapeutics for life-threatening diseases through the application of its proprietary drug delivery and targeting technologies, PEG Modification, Pro Drug/Transport technology and Single-Chain Antigen-Binding (SCA (Single Connector Attachment) An 80-pin plug and socket used to connect peripherals. With a SCSI drive, it rolls three cables (power, data channel and ID configuration) into one connector for fast installation and removal. (R)) Protein technology. Enzon's research activities are focused primarily in the area of oncology. In addition to two FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved products, Enzon has several products in various stages of clinical development by itself and with partners, including PEG-Intron A with Schering-Plough, which is in Phase III clinical trials for hepatitis C Hepatitis C Definition Hepatitis C is a form of liver inflammation that causes primarily a long-lasting (chronic) disease. Acute (newly developed) hepatitis C is rarely observed as the early disease is generally quite mild. , malignant melanoma Malignant Melanoma Definition Malignant melanoma is a type of cancer arising from the melanocyte cells of the skin. Melanocytes are cells in the skin that produce a pigment called melanin. , chronic myelogenous leukemia Chronic myelogenous leukemia (CML) Also called chronic myelocytic leukemia, malignant disorder that involves abnormal accumulation of white cells in the marrow and bloodstream. Mentioned in: Bone Marrow Transplantation and in combination treatment with Schering-Plough's product Rebetol(r) for the treatment of hepatitis C. Enzon develops and markets products on its own and through its alliance partners, which in addition to Schering-Plough include Alexion Pharmaceuticals, Baxter Healthcare, Bristol-Myers Squibb, Eli Lilly, and Rhone-Poulenc Rorer Pharmaceuticals. This release is also available at http://www.enzon.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion